Short answer
PULSE BIOSCIENCES, INC. (PLSE) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 8.01 (Other Events). PRECISE-BTN enrollment completed at 100 patients, doubled from the original 50-patient design.
PULSE BIOSCIENCES, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- PRECISE-BTN enrollment completed at 100 patients, doubled from the original 50-patient design
- All patients enrolled across three U.S. clinical sites within approximately 12 months
- First enrolled patient completed final 12-month follow-up, advancing clinical endpoint data collection
- Study evaluates nPulse Vybrance for safety, nodule reduction, symptom relief, hormone normalization, and quality-of-life improvements
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PULSE BIOSCIENCES, INC. 8-K filings
Get the next PLSE 8-K as it lands
Follow PLSE for push alerts, or ask the research agent what this filing means.